Matthew J Matasar MD (He/Him)

PubMed

• 1 citations
  Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.
  Max S Topp, Matthew Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes
  Blood. 2025-04-03
• Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.
  Niloufer Khan, Parastoo B Dahi, Farhad Khimani, Andrei Shustov, Mazyar Shadman
  Blood Advances. 2025-04-03
• Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
  Elise A Chong, Elicia Penuel, Ellen B Napier, Rachel K Lundberg, Lihua E Budde
  Blood Advances. 2025-02-25

Abstracts/Posters

• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicit...
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Matthew J Matasar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Res... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018